Your browser doesn't support javascript.
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.
Reynolds, Catherine J; Pade, Corinna; Gibbons, Joseph M; Otter, Ashley D; Lin, Kai-Min; Muñoz Sandoval, Diana; Pieper, Franziska P; Butler, David K; Liu, Siyi; Joy, George; Forooghi, Nasim; Treibel, Thomas A; Manisty, Charlotte; Moon, James C; Semper, Amanda; Brooks, Tim; McKnight, Áine; Altmann, Daniel M; Boyton, Rosemary J; Abbass, Hakam; Abiodun, Aderonke; Alfarih, Mashael; Alldis, Zoe; Altmann, Daniel M; Amin, Oliver E; Andiapen, Mervyn; Artico, Jessica; Augusto, João B; Baca, Georgina L; Bailey, Sasha N L; Bhuva, Anish N; Boulter, Alex; Bowles, Ruth; Boyton, Rosemary J; Bracken, Olivia V; O'Brien, Ben; Brooks, Tim; Bullock, Natalie; Butler, David K; Captur, Gabriella; Carr, Olivia; Champion, Nicola; Chan, Carmen; Chandran, Aneesh; Coleman, Tom; Couto de Sousa, Jorge; Couto-Parada, Xose; Cross, Eleanor; Cutino-Moguel, Teresa; D'Arcangelo, Silvia.
  • Reynolds CJ; Department of Infectious Disease, Imperial College London, London, UK.
  • Pade C; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Gibbons JM; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Otter AD; UK Health Security Agency, Porton Down, UK.
  • Lin KM; Department of Infectious Disease, Imperial College London, London, UK.
  • Muñoz Sandoval D; Department of Infectious Disease, Imperial College London, London, UK.
  • Pieper FP; Department of Infectious Disease, Imperial College London, London, UK.
  • Butler DK; Department of Infectious Disease, Imperial College London, London, UK.
  • Liu S; Department of Infectious Disease, Imperial College London, London, UK.
  • Joy G; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Forooghi N; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Treibel TA; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Manisty C; Institute of Cardiovascular Science, University College London, London, UK.
  • Moon JC; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Semper A; Institute of Cardiovascular Science, University College London, London, UK.
  • Altmann DM; UK Health Security Agency, Porton Down, UK.
  • Boyton RJ; UK Health Security Agency, Porton Down, UK.
  • Abbass H; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Abiodun A; Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Alfarih M; Department of Infectious Disease, Imperial College London, London, UK.
  • Alldis Z; Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Science ; 377(6603): eabq1841, 2022 07 15.
Article in English | MEDLINE | ID: covidwho-1891726
ABSTRACT
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: B-Lymphocytes / T-Lymphocytes / Immunization, Secondary / SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Science Year: 2022 Document Type: Article Affiliation country: Science.abq1841

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: B-Lymphocytes / T-Lymphocytes / Immunization, Secondary / SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Science Year: 2022 Document Type: Article Affiliation country: Science.abq1841